Generation Bio

Generation Bio FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Generation Bio (GBIO) as of Nov 10, 2026 is 69.09 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 47.50 % — a change of 45.44% (higher).

FCF Conversion

69.09 %

YoY

45.44%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Generation Bio is 2024 69.09 % . FCF Conversion Rate (FCF/EBITDA) of Generation Bio was 2023 47.50 % . It decreases by 45.44% higher compared to the previous year.

The Generation Bio FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
86.98 USD
Jan 1, 2019
100.00 USD
Jan 1, 2020
98.90 USD
Jan 1, 2021
85.27 USD
Jan 1, 2022
84.22 USD
Jan 1, 2023
47.50 USD
Jan 1, 2024
69.09 USD
The Generation Bio FCF Conversion history
YEARFCF ConversionYoY
69.09 %+45.44%
47.50 %-43.60%
84.22 %-1.23%
85.27 %-13.78%
98.90 %-1.10%
100.00 %+14.97%
86.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio Stock analysis

What does Generation Bio do? Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate. Generation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Generation Bio stock

FCF Conversion Rate (FCF/EBITDA) of Generation Bio is 69.09 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Generation Bio changed from 47.50 % to 69.09 %, representing a 45.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Generation Bio since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Generation Bio with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Generation Bio

All Key Metrics — Generation Bio